These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 5718434)

  • 21. Hypertonic salt solution of superficial membrane proteins from ATPc+ mouse ascites tumour which retain tumour specific antigenic properties.
    Pitzurra M; Marconi P; Bistoni F
    Boll Ist Sieroter Milan; 1973; 52(4):346-8. PubMed ID: 4130350
    [No Abstract]   [Full Text] [Related]  

  • 22. Antigenic characteristics of metastasizing and nonmetastasizing mammary adenocarcinomata of rat.
    Ghosh SK; Roholt OA; Kim U
    Prog Clin Biol Res; 1983; 133():227-33. PubMed ID: 6622494
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumor antigens. I. Immunological studies of tissue and tumor antigens and serum protein production by a mouse rhabdomyosarcoma and mammary adenocarcinoma.
    Phillips ME
    Int Arch Allergy Appl Immunol; 1970; 37(1):54-66. PubMed ID: 4983341
    [No Abstract]   [Full Text] [Related]  

  • 24. Altered tumor growth in vivo after immunization of mice with antitumor antibodies.
    Gorczynski RM; Kennedy M; Polidoulis I; Price GB
    Cancer Res; 1984 Aug; 44(8):3291-8. PubMed ID: 6744263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Ia antigens on the murine adenocarcinoma LT-85.
    Giedlin MA; Martin WJ; Callahan GN
    J Natl Cancer Inst; 1983 Oct; 71(4):825-34. PubMed ID: 6578374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavior of skin allorafts in backcross progeny of tolerant males.
    Steinmuller D
    J Natl Cancer Inst; 1967 Dec; 39(6):1247-51. PubMed ID: 4865582
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
    J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor immunity induced by hybrid murine tumor cells: requirements for optimal immunization.
    McCune CS; O'Donnell RW; Horan PK; Budd HS; Spennacchio JL; Chuang C; Henshaw EC
    J Natl Cancer Inst; 1982 Sep; 69(3):647-52. PubMed ID: 6955557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occurrence of shared nonviral tumor-associated transplantation-type antigens among C3H/He mammary carcinomas.
    Vaage J
    Cancer Res; 1984 May; 44(5):1876-9. PubMed ID: 6201265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas.
    Simmons RL; Rios A
    J Immunol; 1973 Dec; 111(6):1820-5. PubMed ID: 4750868
    [No Abstract]   [Full Text] [Related]  

  • 32. Soluble factors produced during an immune response regulate Ia antigen expression by murine adenocarcinoma and fibrosarcoma cells.
    Callahan GN
    J Immunol; 1984 May; 132(5):2649-57. PubMed ID: 6201554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of Thy 1.2 antigen expression on the surfaces of mouse mammary epithelial cells.
    Thompson K
    J Natl Cancer Inst; 1981 Jul; 67(1):143-8. PubMed ID: 6265679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antigens A,B,O in subcellular fractions of normal and neoplastic human tissue].
    Zykov IuV; Timofeev VT; Aleksanian IuT
    Zh Eksp Klin Med; 1970; 10(2):73-7. PubMed ID: 5450099
    [No Abstract]   [Full Text] [Related]  

  • 35. Immune response to inactivated syngeneic mammary adenocarcinoma cells. II. Parameters of immunogenicity in DBA/2 mice.
    DeLustro F; Haskill JS
    J Natl Cancer Inst; 1980 Jan; 64(1):131-7. PubMed ID: 6928038
    [No Abstract]   [Full Text] [Related]  

  • 36. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
    Boyer CM; Kreider JW; Bartlett GL
    Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes in antitumor resistance during chemical carcinogenesis].
    Savinskaia AP
    Biull Eksp Biol Med; 1984 Aug; 98(8):226-8. PubMed ID: 6432073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma.
    Cavallo F; Di Pierro F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Forni M; Modesti A; Forni G
    Cancer Res; 1993 Nov; 53(21):5067-70. PubMed ID: 8221636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Differences between the mitochondria of mammary glands of C3H mice and those of grafted mammary carcinomas of the same line].
    Bourlioux P; Tran Ba Loc P
    C R Seances Soc Biol Fil; 1967 Sep; 161(3):502-7. PubMed ID: 4229376
    [No Abstract]   [Full Text] [Related]  

  • 40. Systemic and in situ natural killer activity in transplanted and spontaneous mammary tumors in C3H/HeN mice.
    Gerson JM; Tagliabue A; Herberman RB
    J Reticuloendothel Soc; 1981 Jan; 29(1):15-21. PubMed ID: 7205815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.